Literature DB >> 12692724

A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.

Bence Sipos1, Simone Möser, Holger Kalthoff, Virag Török, Matthias Löhr, Günter Klöppel.   

Abstract

There are a large number of stable pancreatic ductal carcinoma cell lines that are used by researchers worldwide. Detailed data about their differentiation status and growth features are, however, often lacking. We therefore attempted to classify commonly used pancreatic carcinoma cell lines according to defined cell biological criteria. Twelve pancreatic ductal adenocarcinoma cell lines were cultured as monolayers and spheroids and graded according to their ultrastructural features. The grading system was based on the integrity of membrane structures and on the presence of mucin granules, cell organelles, nuclear and cellular polymorphism, cell polarity, and lumen formation. On the basis of the resulting scores the cell lines were classified as well, moderately, or poorly differentiated. In addition, immunocytochemistry was performed for the markers cytokeratin 7, 8, 18, 19, carcinoembryonic antigen, MUC1 MUC2, MUC5, and MUC6. The population doubling time of monolayer cultures, determined by a tetrazolium salt based proliferation assay was correlated with the ultrastructural grade. The grading of the ultrastructural features of the monolayers, and particularly of the spheroids, revealed that Capan-1 and Capan-2 cells were well differentiated; Colo357, HPAF-2, Aspc-1, A818-4, BxPc3, and Panc89 cells were moderately differentiated and PancTu-I, Panc1, Pt45P1, and MiaPaCa-2 cells poorly differentiated. Membrane-bound MUC1 staining was a characteristic of well differentiated cell lines. The population doubling time of the monolayer cultures was related to the differentiation grade. No relationship was found between the p53, K-ras, DPC4/Smad4, or p16(INK4a) mutation status and the grade of differentiation. We conclude that the proposed ultrastructural grading system combined with the proliferative activity provides a basis for further comparative studies of pancreatic ductal adenocarcinoma cell lines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692724     DOI: 10.1007/s00428-003-0784-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  32 in total

1.  Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas.

Authors:  M Lieber; J Mazzetta; W Nelson-Rees; M Kaplan; G Todaro
Journal:  Int J Cancer       Date:  1975-05-15       Impact factor: 7.396

2.  Activation of the c-K-ras oncogene in a human pancreas carcinoma.

Authors:  H Hirai; T Okabe; Y Anraku; M Fujisawa; A Urabe; F Takaku
Journal:  Biochem Biophys Res Commun       Date:  1985-02-28       Impact factor: 3.575

3.  Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

Authors:  J Fogh; W C Wright; J D Loveless
Journal:  J Natl Cancer Inst       Date:  1977-02       Impact factor: 13.506

4.  Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.

Authors:  P S Moore; B Sipos; S Orlandini; C Sorio; F X Real; N R Lemoine; T Gress; C Bassi; G Klöppel; H Kalthoff; H Ungefroren; M Löhr; A Scarpa
Journal:  Virchows Arch       Date:  2001-12       Impact factor: 4.064

5.  Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma.

Authors:  R T Morgan; L K Woods; G E Moore; L A Quinn; L McGavran; S G Gordon
Journal:  Int J Cancer       Date:  1980-05-15       Impact factor: 7.396

6.  Intermediate filaments as differentiation markers of normal pancreas and pancreas cancer.

Authors:  M H Schüssler; A Skoudy; F Ramaekers; F X Real
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

7.  Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: studies in xenografted tumours and clinico-histopathological correlation in a series of 75 cases.

Authors:  G Klöppel; G Lingenthal; M von Bülow; H F Kern
Journal:  Histopathology       Date:  1985-08       Impact factor: 5.087

8.  Intermediate filaments in rat pancreatic acinar tumors, human ductal carcinomas, and other gastrointestinal malignancies.

Authors:  K H Herzig; M Altmannsberger; U R Fölsch
Journal:  Gastroenterology       Date:  1994-05       Impact factor: 22.682

9.  Expression of intermediate filaments in normal and neoplastic exocrine pancreas.

Authors:  D Santini; C Ceccarelli; G N Martinelli; G Pasquinelli; O Leone; D Marrano; A M Mancini
Journal:  Zentralbl Pathol       Date:  1994-08

10.  Autocrine stimulation of human pancreatic duct-like development by soluble isoforms of epimorphin in vitro.

Authors:  L Lehnert; M M Lerch; Y Hirai; M L Kruse; W Schmiegel; H Kalthoff
Journal:  J Cell Biol       Date:  2001-03-05       Impact factor: 10.539

View more
  132 in total

1.  RNA interference characterization of proteins discovered by proteomic analysis of pancreatic cancer reveals function in cell growth and survival.

Authors:  Candy N Lee; Jenny L Heidbrink; Katherine McKinnon; Victoria Bushman; Henrik Olsen; William FitzHugh; Aiqun Li; Karen Van Orden; Tao He; Steven M Ruben; Paul A Moore
Journal:  Pancreas       Date:  2012-01       Impact factor: 3.327

2.  A genome-wide RNAi screen for polypeptides that alter rpS6 phosphorylation.

Authors:  Angela Papageorgiou; Joseph Avruch
Journal:  Methods Mol Biol       Date:  2012

3.  Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway.

Authors:  Oliver A Kent; Raghu R Chivukula; Michael Mullendore; Erik A Wentzel; Georg Feldmann; Kwang H Lee; Shu Liu; Steven D Leach; Anirban Maitra; Joshua T Mendell
Journal:  Genes Dev       Date:  2010-12-15       Impact factor: 11.361

4.  Oxidative inhibition of Hsp90 disrupts the super-chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo.

Authors:  Sayantani Sarkar; Devawati Dutta; Suman Kumar Samanta; Kaushik Bhattacharya; Bikas Chandra Pal; Jinping Li; Kaustubh Datta; Chhabinath Mandal; Chitra Mandal
Journal:  Int J Cancer       Date:  2012-07-09       Impact factor: 7.396

5.  Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.

Authors:  Nabeel Bardeesy; Kuang-Hung Cheng; Justin H Berger; Gerald C Chu; Jessica Pahler; Peter Olson; Aram F Hezel; James Horner; Gregory Y Lauwers; Douglas Hanahan; Ronald A DePinho
Journal:  Genes Dev       Date:  2006-11-15       Impact factor: 11.361

6.  HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells.

Authors:  Sugiko Watanabe; Yasuaki Ueda; Shin-ichi Akaboshi; Yuko Hino; Yoko Sekita; Mitsuyoshi Nakao
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

7.  NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.

Authors:  Mitali Chattopadhyay; Ravinder Kodela; Gabriela Santiago; Thuy Tien C Le; Niharika Nath; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2020-02-14       Impact factor: 5.858

8.  Detection of micrometastases in peritoneal washings of pancreatic cancer patients by the reverse transcriptase polymerase chain reaction.

Authors:  Kimberly Moore Dalal; Yanghee Woo; Charles Galanis; Mithat Gonen; Laura Tang; Peter Allen; Ronald DeMatteo; Yuman Fong; Daniel G Coit
Journal:  J Gastrointest Surg       Date:  2007-09-19       Impact factor: 3.452

9.  KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes.

Authors:  M Oliverius; D Flasarova; B Mohelnikova-Duchonova; M Ehrlichova; V Hlavac; M Kocik; O Strouhal; P Dvorak; I Ojima; P Soucek
Journal:  Mutagenesis       Date:  2019-12-19       Impact factor: 3.000

10.  TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation.

Authors:  Zhongkui Li; Zhe Chang; Lucia J Chiao; Ya'an Kang; Qianghua Xia; Cihui Zhu; Jason B Fleming; Douglas B Evans; Paul J Chiao
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.